

I hereby certify that this correspondence is being transmitted via the Office electronic filing system to the U.S. Patent and Trademark Office, on the date shown below.

Dated: October 16, 2007 Signature: /Mark D. Russelt/
Mark D. Russelt, Reg. No. 41,281

Docket No.: 2062(240671)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Martin Quibell et al.

Application No.: 10/521,354

Confirmation No.: 9132

Filed: January 14, 2005

Art Unit: 1609

For: BIOLOGICALLY ACTIVE COMPOUNDS

Examiner: R.H. Havlin

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed April 16, 2007 (the "Restriction Requirement"), please consider the remarks set forth below. A request for an extension of time accompanies this paper, which is therefore believed to be timely filed.

REMARKS

The Restriction Requirement

Applicants wish to thank the Examiner for permitting a telephone conference with their undersigned representative on October 15, 2007, regarding the requirement for restriction. The restriction requirement and a proper response thereto were discussed; the Examiner indicated that Applicants should elect a species for search purposes.

In response to the Restriction Requirement, Applicants elect the claims of Group II, claims 1-31, 33, 35, 37-39, 41, 43-45, 47, 49-52, 58, and 60-74 (in part), drawn to compounds, compositions and methods of use thereof, wherein U and B have the values shown in the Restriction Requirement.